Amgen 2012 Annual Report Download - page 40

Download and view the complete annual report

Please find page 40 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

33
Under the terms of the agreement, approximately 65% of related development costs for the 2012-2014 periods will be funded
by AstraZeneca; thereafter, the companies will share costs equally. If approved for sale, Amgen would receive a low-single-digit
royalty rate for brodalumab and a mid-single-digit royalty rate for the rest of the portfolio, after which the worldwide
commercialization profits and losses related to the collaboration products would be shared equally.
UCB
We are in a collaboration with UCB for the development and commercialization of romosozumab. We have the rights to
commercialize romosozumab for all indications in the United States, Canada, Mexico and Japan. UCB has the rights for all EU
members at the time of first regulatory approval, Australia and New Zealand. Prior to commercialization, countries that have not
been initially designated will be designated to Amgen or UCB in accordance with the terms of the agreement.
Generally, development costs are shared equally and we will share equally in the worldwide commercialization profits and
losses related to the collaboration after accounting for expenses.
DaVita Inc.
We are in a seven-year supply agreement with DaVita that commenced January 1, 2012. Pursuant to this agreement, we will
supply EPOGEN® in amounts necessary to meet no less than 90% of DaVita's and its affiliates' requirements for ESAs used in
providing dialysis services in the United States and Puerto Rico. The agreement may be terminated by either party before expiration
of its term in the event of certain breaches of the agreement by the other party.
Human Resources
As of December 31, 2012, Amgen had approximately 18,000 staff members. We consider our staff relations to be good.
Executive Officers of the Registrant
The executive officers of the Company as of February 13, 2013, are as follows:
Mr. Robert A. Bradway, age 50, has served as a director of the Company since October 2011 and Chairman of the Board of
Directors since January 1, 2013. Mr. Bradway has been the Company's President since May 2010 and Chief Executive Officer
since May 2012. From May 2010 to May 2012, Mr. Bradway served as the Company's President and Chief Operating Officer.
Mr. Bradway joined the Company in 2006 as Vice President, Operations Strategy, and served as Executive Vice President and
Chief Financial Officer from April 2007 to May 2010. Prior to joining the Company, he was a Managing Director at Morgan
Stanley in London where he had responsibility for the firm's banking department and corporate finance activities in Europe and
focused on healthcare.
Mr. Madhavan (Madhu) Balachandran, age 62, became Executive Vice President, Operations in August 2012. Mr.
Balachandran joined the Company in 1997 and has held leadership positions in engineering, information systems and operations.
From October 2007 to August 2012, Mr. Balachandran was Senior Vice President, Manufacturing. From February 2007 to October
2007, Mr. Balachandran was Vice President, Site Operations. From May 2002 to February 2007, Mr. Balachandran was Vice
President, Puerto Rico Operations. Prior to 2002, Mr. Balachandran served as Associate Director, Capital Projects, before his
promotion to Director, Engineering, and then to Vice President, Information Management.
Dr. Sean E. Harper, age 50, became Executive Vice President, Research and Development in February 2012. Dr. Harper
joined the Company in 2002 and has held leadership roles in early development, medical sciences and global regulatory and safety.
Dr. Harper served as Senior Vice President, Global Development and Corporate Chief Medical Officer from March 2007 to
February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.
Mr. Anthony C. Hooper, age 58, became Executive Vice President, Global Commercial Operations, in October 2011. From
March 2010 to October 2011, Mr. Hooper was Senior Vice President, Commercial Operations and President, U.S., Japan and
Intercontinental of BMS, a pharmaceutical company. From January 2009 to March 2010, Mr. Hooper was President, Americas of
BMS. From January 2004 to January 2009, Mr. Hooper was President, U.S. Pharmaceuticals, Worldwide Pharmaceuticals Group,
a division of BMS. Prior to that, Mr. Hooper held various senior leadership positions at BMS. In his roles at BMS, Mr. Hooper
led commercial operations in mature and emerging markets. Prior to joining BMS, Mr. Hooper was Assistant Vice President of
Global Marketing for Wyeth Laboratories.
Mr. Brian McNamee, age 56, became Senior Vice President, Human Resources in June 2001. From November 1999 to June
2001, Mr. McNamee served as Vice President of Human Resources at Dell Computer Corp. From 1998 to 1999, Mr. McNamee
served as Senior Vice President, Human Resources for the National Broadcasting Corporation, a division of GE. From July 1988